No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Gm-csf |
Regramostim |
D05712 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[4] 11, 46, 51, 229 |
2 |
Gm-csf (granulocyte-macrophage colony-stimulating factor, sargramostim) |
Sargramostim |
D05803 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
3 |
Gm-csf inhalation therapy |
Regramostim |
D05712 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
4 |
Granulocyte-macrophage colony stimulating factor (gm-csf) |
Regramostim |
D05712 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
5 |
Leukine |
Sargramostim |
D05803 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
6 |
Methionine |
Methionine |
D00019, D04983 |
- |
- |
[6] 34, 75, 84, 93, 229, 300 |
7 |
Molgramostim |
Molgramostim |
D05066 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[2] 229, 299 |
8 |
Molgramostim 300 mcg nebuliser solution |
Molgramostim |
D05066 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
9 |
Molgramostim nebuliser solution 300 mcg |
Molgramostim |
D05066 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
10 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
11 |
Rhgm-csf |
Regramostim |
D05712 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[1] 229 |
12 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
13 |
Sargramostim |
Sargramostim |
D05803 |
[1] CSF2RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[6] 6, 28, 60, 62, 96, 229 |
14 |
Vitamin b12 |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
[4] 6, 201, 229, 299 |
15 |
Vitamin b12, b9, b6, c supplementation |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
[1] 229 |